While potent monoclonal antibodies against ricin were introduced over the years, the question whether increasing antibody affinity enables better toxin neutralization was not fully addressed yet. The aim of this study was to characterize the contribution of antibody affinity to the ricin neutralization potential of the antibody. cHD23 monoclonal antibody that targets the toxin B-subunit and interferes with its binding to membranal receptors, was isolated. In order to create antibody clones with improved affinity toward ricin, a scFv-phage display library containing mutated versions of the variable regions of cHD23 was constructed and clones with improved binding of ricin were isolated. Structural modeling of these mutants suggests that the inserted mutations may increase the antibody conformational flexibility thus improving its ability to bind ricin. While it was found that the selected clones exhibited improved neutralization of ricin, the correlation between the K D values and potency was only minor (r = 0.55). However, a positive correlation (r = 0.84) exist between the off-rate values (k off ) of the affinity matured clones and their ability to neutralize ricin. As cell membranes display inordinately large amounts of potential surface binding sites for ricin, it is suggested that antibodies with improved off-rate values block the ability of the toxin to bind to target receptors, in a highly efficient manner. Currently, antibody-based therapy is the most effective treatment for ricin intoxication and it is anticipated that the findings of this study will provide useful information and a possible strategy to design an improved antibody-based therapy for the toxin.
Introduction
Ricin, derived from the plant Ricinus communis, consists of two covalently linked subunits: the A-subunit (RTA) is an N-glycosidase that irreversibly inactivates the 28S rRNA of the mammalian 60S ribosome subunit, and the B-subunit (RTB) is a galactose-specific lectin that mediates the binding of the toxin to cell membranes (Olsnes and Kozlov, 2001) . Being one of the most lethal toxins known, together with its wide availability, ease of production and dissemination, ricin is considered a potential bio-terror agent and is classified as a category B select agent by the Center for Disease Control and Prevention (CDC). Currently, there is no available antidote against ricin exposure, emphasizing the need to develop effective countermeasures. Thus far, the most promising anti-ricin therapy is based on neutralizing antibodies elicited by active vaccination or administered passively (Smallshaw and Vitetta, 2011; Gal et al., 2014; Noy-Porat et al., 2016) .
Improving the affinity of an antibody, often results in a concomitant improvement of its neutralizing activity (Barbas et al., 1994; Maynard et al., 2002; Rajpal et al., 2005; Rathanaswami et al., 2005; Riano-Umbarila et al., 2005; Wu et al., 2005; Dufner et al., 2006; Van Blarcom et al., 2010) . While several ricin-neutralizing monoclonal antibodies were developed over the past years and despite their importance to post-exposure therapy, the question whether increasing antibody affinity will enable better toxin neutralization was not yet fully addressed. Indeed, the general notion is that a positive correlation between the two parameters does exist. Yet, this concept is mainly based on studies that have compared the activity of different antibodies (targeting different epitopes) that exhibit various affinities toward ricin (Smallshaw and Vitetta, 2011; Gal et al., 2014; Noy-Porat et al., 2016) . Recently, it was shown that converting single-domain anti-ricin antibodies from monomers into heterodimers, enhanced both their apparent affinity and neutralization activity (Vance et al., 2013) , while affinity maturation of the antiricin monoclonal antibody C4C13 did not improved toxin neutralization (Luo et al., 2013) . We therefore set out in this study, as part of ongoing efforts to develop effective countermeasures to ricin, to further investigate the possibility to enhance the neutralizing activity of anti-ricin monoclonal antibody via in vitro affinity maturation.
Materials and Methods
Hybridoma production B-cell hybridomas were derived from spleen of BALB/c mouse immunized with ricin-holotoxin, essentially as described before (Rosenfeld et al., 2009) . Ricin-specific IgG secreting hybridomas were screened by enzyme-linked immunosorbent assay (ELISA) as described below and positive hybridomas were cloned at least twice by limiting dilution.
Cloning and expression of the cHD23 antibody
Chimerization of the murine HD23 antibody was carried out essentially as described before (Rosenfeld et al., 2009) . The expression of the WT and the mutant forms of cHD23 was performed using FreeStyle Max 293 cells (Life technologies, USA) that were transiently transfected with a plasmid encoding for the full length IgG. After a week, the supernatant was collected and the antibodies were purified on HiTrap Protein-A column (GE healthcare, Sweden).
Mutated HD23_scFv library construction
HD23_scFv wild-type gene was randomized using error-prone PCR as described (Formant et al., 1995) , using the primers 5′-TATGCGG CCCAGCCGGCCATGGCC-3′ and 5′-CGTTTGATTTCCAGCTT GGTGCCTCCACCGAAC-3′. PCR products were then purified and cloned into the pCC16 plasmid (Azriel- Rosenfeld et al., 2004) between NcoI/NotI sites and transformed to MC1061F′ electrocompetent cells (Lucigen, USA). Library of 1.5e6 clones was created, carrying moderate to high frequency mutagenesis, with average of 10 mutations per scFv fragment.
Panning of phage-libraries
Phage display library amplification, phage packaging, panning and screening were performed as described recently (Noy-Porat et al., 2016) . Panning against biotin-labeled ricin was performed using streptavidin-coated magnetic beads (Dynabeads M-280, 10 mg/mL, Invitrogen, Carlsbad, CA, USA). Phage input titers of 4e10 and 2e9 PFU/ml were used in the first two and at the third panning cycles, respectively. Single colonies were randomly picked from the third panning output, scFvs sequences were determined and phages were rescued and tested for their binding to ricin using ELISA.
In vitro neutralization assay
Ub-FL cells (HeLa cells stably expressed ubiquitin-luciferase) (Luker et al., 2003) were kindly provided by Professor Piwnica-Worms (University of Texas, MD Anderson Cancer Center, USA). Cells were cultured in DMEM (Biological Industries, Beit Haemek, Israel) supplemented with 10% FCS. In order to determine the neutralization activity of the anti-ricin antibodies (Gal et al., 2015) , cells were seeded in 96-wells plates (1.5 × 10 4 cells/well), 16 h prior to the experiment.
Ricin (5 ng/ml) was mixed with increasing concentration of the monoclonal antibodies for about 10 min and the mixtures were then incubated with the Ub-FL cultured cells for 24 h. The culture medium was then aspirated and replaced by a fresh culture medium containing 10 μM of MG132 (Sigma-Aldrich, Israel) and the cells were incubated for another hour. Cells were lysed by the addition of 50 μl lysis buffer (Promega, USA) and the residual luciferase activity in each well was then determined by mixing equal volumes of the cell lysate and luciferine (Promega, USA) followed by immediate measurement of the luminescence levels. The residual luciferase activity in the cell-culture wells was plotted as percent of luminescence levels obtained from untreated cells and the curves were fitted using Prism software (GraphPad Software Inc.). For all the tested antibody clones, at least one experimental point have reached the 100% saturation value. Each experiment was repeated at least 2 times and the graphs are of representative experiments.
ELISA
Maxisorp 96-well microtiter plates (Nunc, Roskilde, Denmark) were coated overnight with 5 μg/ml of antigen (50 μl/well) in NaHCO 3 buffer (50 mM, pH 9.6), washed and blocked with PBST (0.05% Tween 20, 2% BSA in PBS) at room temperature for 1 h. Samples were serially diluted in PBST and the plates were then incubated for 1 h at 37°C. Plates were washed with PBST, incubated with the detecting antibody and then developed using PNPP.
Europium-nanoparticles conjugation
Eu(III)-chelated dyed particles (Thermo Fischer Scientific) were activated using N-(3-dimethylaminoprpyl)-N′-ethyl-carboiimid-hydrochloride (EDC) and N-hydroxysulfosuccinimide (sulfo-NHS) (Kokko et al., 2007) . The activated particles were washed twice in 20 mM MES buffer, pH 6.1 and reacted overnight with ricin that was preequilibrate using the same buffer. The ricin conjugated particles (Euricin) were then washed several times with 20 mM Tris HCl pH 9.0, 0.1% Tween 20.
ASF binding assay
Maxisorp 96-well microtiter plates were coated overnight with 5 μg/ml of ASF (Sigma-Aldrich, Israel) in NaHCO 3 buffer, washed and blocked with PBST. Eu-ricin was mixed with increasing concentrations of cHD23 and the mixture was added to the ASF-coated wells for 1 h. Plates were then washed with PBST, incubated with enhancement solution (PerkinElmer) and the amount of bound Eu-ricin was determined using time-resolved fluorimeter (Victor3, PerkinElmer). Binding was expressed as percent of total binding (in the absence of antibody), and the maximal binding signal is below the assay detection limit.
Affinity measurements
Binding studies were carried out using biolayer interferometry (BLI) by the Octet Red system (ForteBio). All steps were performed at 30°C with shaking at 1500 rpm in a 96-well plate containing 200 μl per well. Purified antibodies were biotinylated using EZ-Link sulfo-NHSbiotin kit (Pierce) and the biotinylation did not affect the binding of the antibodies. Streptavidin-coated biosensors were loaded with biotinylated antibodies (5 μg/ml) for 300 s (the loaded antibody did not saturate the sensor) followed by washing. The sensors were then reacted for 300 s with increasing concentrations of ricin (association phase) and then moved to buffer containing wells for another 300 s (dissociation phase). Binding and dissociation were measured as changes over time in light interference, and curves are presented after subtraction of parallel measurements from unloaded biosensors.
Antibody modeling
Models of the WT cHD23 and two variants, 27/24.4 and 24.2, were generated using the AbPredict method (Lapidoth et al., 2015) (Norn et al., 2017) within the Rosetta software suite for biomolecular modeling (Das and Baker, 2008) . Briefly, AbPredict selects backbone conformations of the V H , V L and HCDR3 and LCDR3 segments: starting from a randomly selected set of backbone conformations of the same length as the segments in the query antibodies, AbPredict selected different conformations for these segments using 150 steps of a simulated-annealing Monte Carlo search for the lowest-energy conformation. The 3000 models thus generated were clustered using BCL clustering (Heinze et al., 2015) , and representatives from the three largest clusters were visually inspected. All energy calculations used the talaris2014 all-atom Rosetta energy function, which is dominated by van der Waals, hydrogen bonding, solvation, and electrostatics with a distance-dependent dielectric coefficient (Leaver-Fay et al., 2015) .
Results
Chimerization and characterization of cHD23 antibody B-cells hybridomas were generated from the spleen of ricin-holotoxin immunized BALB/c mouse and screened for those secreting ricinbinding IgGs. Out of the positive clones, antibody HD23 was chosen for chimerization based upon its marked and specific binding to ricin and its ability to neutralize ricin. The variable region genes (VH and VL) of HD23 were amplified and fused to human constant region genes (Cγ1 and Ck, respectively). Subsequently, the construct was introduced into a mammalian expression-system and the recombinant chimeric antibody (cHD23) was stably produced by CHO cells, as described previously (Rosenfeld et al., 2009) . The chimeric cHD23 antibody retained full binding and neutralization capabilities of the parental murine HD23 antibody (data not shown).
To determine to which ricin-subunit, the cHD23 antibody binds, the binding properties of this antibody to each of the separated ricin subunits (RTA and RTB) were evaluated by ELISA. It was found that cHD23 binds only to RTB, albeit to a much lesser extent than to the holotoxin (Fig. 1) . This observation might be a result of partial denaturation of the cHD23 target epitope due to the dissociation of RTB from RTA.
We have recently developed a sensitive in vitro assay to characterize the neutralizing activity of polyclonal and monoclonal antibodies, by measuring the effect of ricin on the intracellular luciferase levels in Ub-FL cells (Gal et al., 2015) . To determine the neutralization efficacy of cHD23, Ub-FL cells were incubated with ricin in the presence of increasing concentrations of the antibody for 24 h and the intracellular luciferase levels were then determined. As expected, there is a clear dose-response curve of ricin neutralization as a function of cHD23 concentrations (Fig. 2) and the effective antibody dose needed to neutralize 50% of ricin activity (ED 50 ) was found to be 51 nM (Table I) .
The primary mechanism of ricin neutralization by RTB-binding antibodies is by interfering with the toxin binding to cell surface glycoproteins (O'Hara et al., 2011) . We have therefore evaluated the capability of cHD23 to inhibit the binding of ricin to asialofetuin (ASF), a surrogate glycoprotein (McGuinness and Mantis, 2006) . Europium-labeled ricin (Eu-ricin) was added to ASF-coated wells in the presence of increasing concentrations of cHD23 and the residual bound Eu-ricin was measured. Indeed, cHD23 inhibits ricin binding to ASF in a dose-response manner (Fig. 3) where at an antibody concentration of 13 nM, 50% of the ricin molecules were displaced. Fig. 1 Binding of cHD23 to ricin subunits. The reactivity profile of cHD23 determined by ELISA coated with either ricin-holotoxin (circles), RTA (squares), RTB (triangles) or BSA (diamonds) as the antigens. Points are mean ± SEM of triplicates. Fig. 2 In vitro neutralization of ricin. Cultured Ub-FL cells were incubated for 24 h with ricin (5 ng/ml) and increasing concentrations of cHD23 (circles) or non-specific isotype control antibody (diamonds). The intracellular luciferase activity was determined and expressed as percent of activity determined for untreated cells. Points are mean ± SEM of triplicates fitted by non-linear regression.
Affinity maturation of cHD23
The affinity of cHD23 antibody towards ricin was determined using the Octet Red BLI system, in which the biotinylated antibody was immobilized on the Octet Red sensor and the binding profile of ricin (at different concentrations) was monitored (Fig. 4) . Fitting the sensograms with a 1:1 binding model revealed that antibody cHD23 exhibit a K D value of 9.3 nM. To improve the affinity of cHD23, error-prone PCR was used to construct mutated scFv-phage display library with average mutation frequency of 10 mutations per scFv fragment. After three rounds of panning on ricin (reaching calculated enrichment factor of 150) and 360 clones screening, two clones (24 and 27) with improved ricin binding activity were selected for further characterization. Sequence analysis revealed that clone 24 bears 4 mutations, all at the heavy chain, two in Framework 1 and another two, adjacent to each other, in HCDR2 (Fig. 5) . Clone 27 has three mutations, one resides in the heavy chain in Framework 1, immediately next to one of the mutations found in clone 24, and two mutations in the light chain at LCDR1 and LCDR2 (Fig. 5) . Following reformatting of these clones into full length IgG, the affinity of each clone was determined using the Octet Red system. As expected, these two clones exhibit significantly higher affinity toward ricin as compared to the WT antibody (K D values of 8.2 nM (P < 0.05), 4.7 nM (P < 0.01) for clones 24, 27, respectively). For both clones, the major improvement in affinity stems from faster k on values (Table I) .
We next sought to determine the contribution of each mutant on the overall affinity (Fig. 5) . The first step was to evaluate whether the improvement of clone 27 resides from the mutated heavy chain, the light chain or both. To that end, antibodies pairs of either 27VH/ WT-VL or WT-VH/27-VL were constructed and the affinity of each pair was determined. It was found that the mutations in the 27VL (S28G and N54D) chain have no effect on the affinity (data not shown) and that the point mutation in the VH chain (A24G) in itself contributes to the change in affinity toward ricin. Next, we assessed the contribution of the mutation along the VH chain of clone 24 on the overall affinity, finding that clones 24.1 and 24.3, each containing one mutation in HFW1 (E1V and T23A, respectively), have better affinity than the WT (Table I) , while the addition of the two mutations in HCDR2 (clone 24.2, containing mutations: D56S and T58A) results in affinity value similar to the WT, suggesting that they in fact have negative impact on binding. Indeed, in their absence (clone 24.4, containing mutations: E1V and T23A) the affinity value of the mutated antibody is markedly improved (Table I) .
Next, we combined the three mutations at HFW1, Positions: 1 and 23 (of clone 24) and 24 (of clone 27). Indeed, all three combinations, resulted in a marked 3 and 3.9 fold improvement of antibody affinity (2.4 and 3.1 nM for clones 27/24.1 and 27/24.3, respectively; Table I ). Interestingly, the main attribution for this improvement resides from a better k off value, since these two mutants exhibit a slower k on as compared to the WT antibody. Mutated clone bearing the combined three mutations (clone 27/24.4) exhibited only marginal improvement in the overall affinity (2.2 nM, 4.2 fold increase over the WT antibody), indicating that among the mutations found in this study, the most important residues that affect cHD23 binding are those at Positions 1 and 24.
Structure modeling of WT cHD23 and mutants 27/24.3 and 24.2
For each antibody variant we generated three model structures to study the molecular underpinnings of the observed changes in binding affinities. All nine models converged to similar backbone conformations in all segments (<1Å root-mean-square deviation in all segments, except H3), suggesting that the affinity-enhancing mutations do not cause large conformation changes. Variant 27/24.3 introduces two conservative mutations relative to cHD23, A24G Antibody contains mutated heavy chain and WT light chain. Fig. 3 Inhibition of ricin binding to glycoprotein. Ricin-labeled Europium particles (Eu-ricin) were mixed with increasing concentrations of cHD23 (circles) or non-specific isotype control antibody (diamonds) and the mixtures were added to ASF-coated wells and incubated for 1 h. The wells were then washed and the amount of residual bound ricin was determined using timeresolved fluorimeter. Points are mean ± SEM of triplicates expressed as percent of maximal ricin binding, fitted by non-linear regression. Fig. 4 Affinity measurement of cHD23. The affinity of antibody cHD23 was measured using BLI. Biotinylated antibody was immobilized on a streptavidin-biosensor and reacted for 300 s with increasing concentrations of ricin (Black lines, from bottom up: 6.25 nM; 12.5 nM: 25 nM and 50 nM). The sensors were then immersed in buffer for another 300 s (dissociation phase). Red lines: curve fitting of 1:1 binding model. and T23A. Since both mutations reduce the bulk of the sidechains at the affected positions ( Fig. 6A and B) , the models suggest that the mutations may increase this variant's conformational flexibility, which may improve its ability to bind ricin. In contrast, the two mutations in variant 24.2, D56S and T58A, are located on H2 away from the presumed antibody's ricin-binding surface, and the reasons for the minor affinity improvement in this mutant remain unclear ( Fig. 6C and D) .
Improving cHD23 neutralization potency
The effect of affinity maturation of antibody cHD23 on its neutralization potency was studied next. To that end, each antibody mutant clone was tested in the in vitro neutralization assay and the ED 50 values were determined (Table I) . Interestingly, it was found that clones 24 and 27 that exhibit improved k on rate as compared to the WT did not exhibit improved neutralization efficacy. In contrast, the other mutant clones, and especially these bearing the combined mutations did show better neutralization potency as compared to the WT. To further understand what may be the reason for this alleged discrepancy between antibody affinity and its ability to neutralize ricin, we correlated the K D and ED 50 values of the various clones (Fig. 7A) . It was found that while a positive correlation does exist between these two parameters (r = 0.55), it is not statistically significant. However, a very strong correlation (r = 0.84) exist between the off-rate values (k off ) of the various clones and their ability to neutralize ricin (Fig. 7B) . The significant (P < 0.05) correlation between these two parameters fits very well with the findings that the improvement in affinity of clones 24 and 27 (which do not exhibit superior neutralization activity over the WT) resides solely from a faster on-rate values.
Discussion
Since the currently most promising anti-ricin therapy is based on passive administration of neutralizing antibodies, understanding the role of affinity in antibody activity is essential for developing efficient countermeasures. In this study, we demonstrate for the first time that a positive correlation exists between antibody affinity toward ricin and its ability to neutralize the toxin activity. Moreover, the major contribution of this improvement resides from a slower dissociation constant of the affinity matures clones. Antibody cHD23 targets the RTB subunit and interferes with the binding of ricin to the glycoproteins that serve as its membranal receptors. It has been established before, that the cell membrane display inordinately large amounts of potential surface binding sites for ricin (above 10 7 molecules per cell) (Sandvig et al., 1976) and that the affinity of the toxin toward these binding sites is in the order of 10 −7 to 10 −8 M (Baenziger and Fiete, 1979) . These parameters indicate that ricin binds to the membrane in high avidity, therefore posing a tough challenge to the ability of RTB-binding antibodies, such as cHD23, to neutralize the binding of the toxin to the receptors. It is therefore logical to assume that antiricin antibodies with improved off-rate values will provide better neutralization values, as was shown in this study. Reinforcement of that notion, though not directly, may arise from a recent work that demonstrated better neutralization of ricin upon multimerization of anti-RTB single-domain VHH as compared to the activity of monomers (Vance et al., 2013) . Interestingly, affinity maturation of another anti-RTB antibody (Luo et al., 2013) did not resulted in a significant improved neutralization activity, however due to insufficient data regarding the exact changes in the on/off rates, further comparison is not applicable. In the in vitro neutralization assay, a 500 molar excess of antibody was required in order to neutralize 50% of the toxin. In the current assay setup, a short incubation period (10 min) was applied. As demonstrated in the binding assay, long incubation periods are needed in order to reach saturation, therefore it can be hypothesized that longer incubation periods will result in lowering the amount of antibody needed to neutralize the same amount of toxin. In accordance with this notion, we have previously demonstrated (Noy-Porat et al., 2016) that for anti-ricin antibodies derived from a non-human scFv-phage display library, displaying affinities similar to that of the cHD23 antibody, a 1000 fold excess was needed in order to neutralize ricin in the similar assay, and that for higher affinity antibodies, much lower concentrations of neutralizing antibodies were needed.
Affinity maturation of neutralizing antibodies is widely applied, and in most cases a positive correlation between affinity and potency was demonstrated (Dufner et al., 2006) . The selection process for binding clones with improved potency can be manipulated to allow for selecting faster-binding clones (improved k on ) or such displaying slower k off values and examples exist to support each strategy (Maynard et al., 2002; Wu et al., 2005; Dufner et al., 2006) . Here, the fact that the panning process did not favor either of the two possibilities enables us to isolate clones with improved k on rate as well as clones that exhibit only improved k off rates, thus allowing us to determine which of the two has the most significant effect on ricin neutralization. These results may suggest that in the future, affinity maturation of anti-RTB neutralizing antibodies should favor isolation of the slow-off rates clones. We believe that further studies aiming to determine whether similar correlations exists between affinity and neutralization potency of anti-RTA antibodies should be sought for.
To conclude, we have demonstrated that improving the affinity of ricin-neutralizing antibodies and especially their off-rate kinetics enables better blockage of the toxin activity. As antibody-based therapy is currently the promising and most effective treatment for postexposure treatments against ricin intoxication, it is anticipated that the findings of this study will provide useful information and a possible strategy to design an improved antibody-based therapy for the toxin. Table I . The Pearson nonparametric correlation coefficient (r) and the coefficient of determination (r 2 ) values are indicated within the graphs.
